The Personalized Cancer ImmunoTherapy Program (PCITP) is an initiative born from funds awarded through the Genome Canada (in partnership with Genome Quebec and the Canadian Institutes of Health Research) Large-Scale Applied Research Project Competition in Genomics and Personalized Health. This competition was established to fund large-scale projects for which the proposed "omic" R&D and technologies would translate in better patient care while improving the cost-effectiveness of the health-care system. Our principal focus is the development and clinical implementation of innovative personalized anti-cancer immunotherapies, an entirely different approach to treating cancer.